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ABSTRACT
Introduction: This ﬁrst-time-in-humans study assessed the
safety, pharmacokinetics (PK), pharmacodynamics (PD),
and clinical activity of GSK2879552 in patients with
relapsed or refractory SCLC.
Methods: This phase I, multicenter, open-label study
(NCT02034123) enrolled patients (18 years old) with
relapsed or refractory SCLC (after 1 platinum-containing
chemotherapy or refusal of standard therapy). Part 1 was
a dose-escalation study; Part 2 was a dose-expansion study.
Dose escalations were based on safety, PK, and PD. The
primary end point (Part 1) was to determine the safety,
tolerability, and recommended dose and regimen of
GSK2879552. Secondary end points were to characterize
PK and PD parameters and measure disease control rate at
week 16. Part 2 was not conducted.
Results: Between February 4, 2014, and April 18, 2017, a
total of 29 patients were allocated to one of nine dose
cohorts (0.25 mg–3 mg once daily and 3-mg or 4-mg
intermittent dosing). In all, 22 patients completed the
study; 7 withdrew, primarily owing to adverse events (AEs).
Most patients (24 of 29 [83%]) had at least one treatmentrelated AE, most commonly thrombocytopenia (12 of 29
[41%]). Twelve serious AEs (SAEs) were reported by nine
patients; six were considered treatment related, the most
common of which was encephalopathy (four SAEs). Three
patients died; one death was related to SAEs. PK was
characterized by rapid absorption, slow elimination, and a
dose-proportional increase in exposure.
Conclusions: GSK2879552 is a potent, selective inhibitor
of lysine demethylase 1A and has demonstrated favorable
PK properties but provided poor disease control and a high
AE rate in patients with SCLC. The study was terminated,
as the risk-beneﬁt proﬁle did not favor continuation.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: GSK2879552; Small cell lung carcinoma; Pharmacokinetics; Pharmacodynamics; Safety

Introduction
Lung cancer is the leading cause of cancer death in
the United States, accounting for an estimated 154,050
deaths in 2018, with 234,030 new cases predicted in the
same year.1 SCLC accounts for approximately 10% to
15% of all diagnosed lung cancers.1,2 SCLC is a highly
malignant form of lung cancer, and its prognosis is poor,
with an estimated 5-year survival rate of only 6%.2-4
Chemotherapy has been the standard of systemic treatment for SCLC for several decades; however, although
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SCLC is initially responsive to chemotherapy, relapse is
common and the response to second-line therapy is
poor, with survival of less than 6 months.5,6 In addition,
the overall median survival of patients with SCLC was
found to be unchanged between 1983 and 2012,
remaining at just 7 months throughout the period and
thus highlighting the urgent need for novel treatments.3,4
More recent studies of combination therapies, such as
the addition of atezolizumab to carboplatin and etoposide chemotherapies, have demonstrated signiﬁcantly
longer overall survival and progression-free survival
rates compared with placebo; however, the gains are
modest (median 2 months’ additional overall survival
compared with placebo).7
Epigenetic dysregulation is an important pathogenic
mechanism in many cancers, including SCLC,8 and therapies that target epigenetic mediators have been shown
to be successful in cancer.9 Lysine-demethylase 1A
(KDM1A [also known by the alias name lysine-speciﬁc
histone demethylase 1A and the alias symbol LSD1]) is
a histone demethylase, which catalyzes the removal of
mono- and di-methyl groups on histone H3 lysine 4
(markers of active transcription) as part of a complex
including the enzymes REST copressor 1 (RCOR1 [also
known by the alias COREST]) and histone deacetylase,
leading to suppression of gene expression.10,11 KDM1A
has been shown to be crucial for a range of cellular
processes, including the regulation of pluripotency, selfrenewal, and cellular differentiation.12-14 KDM1A is
overexpressed in primary SCLC,15 and its inhibition in
acute myeloid leukemia (AML) has been shown to
relieve the differentiation block, thereby exerting an
antileukemic effect and sensitizing AML cells to anticancer therapy.16,17 Furthermore, inhibition of KDM1A
provided an antileukemic effect in secondary engraftment models, indicating an effect on the leukemiainitiating cell population and further suggesting a role
for KDM1A in the self-renewal of cancer stem cells.18
Both SCLC and AML are poorly differentiated
tumors19,20; thus, inhibition of KDM1A may invoke a
similar differentiation mechanism in SCLC.
GSK2879552 is a potent, selective, mechanismbased, irreversible inhibitor of KDM1A/RCOR1 activity.15 GSK2879552 has been shown to induce the
expression of putative KDM1A target genes and
demonstrate potent, predominantly cytostatic, antiproliferative activity in SCLC cell lines and tumor
xenograft models, highlighting the potential of
GSK2879552 for treatment of SCLC.15,21 This ﬁrsttime-in-humans, open-label, dose-escalation study
aimed to assess the safety, pharmacokinetics (PK),
pharmacodynamics (PD), and preliminary clinical
activity of GSK2879552 in patients with relapsed or
refractory SCLC.
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Materials and Methods
Study Design
This was a phase I, open-label, multicenter, nonrandomized, two-part study designed to evaluate the
safety, tolerability, PK, PD, and clinical activity of
GSK2879552 given orally to patients with relapsed or refractory SCLC (200858, NCT02034123). The study was
planned as two parts: Part 1 was a dose-escalation study to
determine the recommended dose for Part 2 based on
safety, tolerability, and PK and PD data; Part 2 was to be a
dose-expansion study planned to further evaluate the
safety and tolerability of GSK2879552 at the recommended
dose and determine clinical activity (Supplementary Fig. 1).
This study was conducted at three centers in the
United States, one center in France, and four centers in
Spain. The ﬁrst patient was enrolled on February 4,
2014, and the last patient visit was completed on April
18, 2017. On June 13, 2017, the study was terminated, as
the risk-beneﬁt proﬁle in relapsed or refractory SCLC did
not favor continuation of the study. There were no active
subjects on study when the study was terminated. Part
2 of the study was not conducted.
The study protocol, amendments, and informed consent form was reviewed and approved by a national,
regional, or investigational center ethics committee or
institutional review board. Written informed consent
was obtained from each patient before the performance
of any study-speciﬁc procedures. The study was conducted in accordance with the guidelines of the International Council for Harmonization and the ethical
principles outlined in the Declaration of Helsinki 2008.

Study Population
Eligible patients (18 years old) had recurrent or
refractory SCLC (after receiving 1 prior standard
platinum-containing chemotherapy regimen, or if standard therapy was refused) with an Eastern Cooperative
Oncology Group performance status of 0 or 1. Full inclusion and exclusion criteria are included in the
Supplementary Materials.
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Council for Harmonization of Technical Requirements for
Pharmaceuticals for Human Use S9 guidelines.22
The dose-escalation phase followed a Bayesian adaptive design with one patient per cohort until a study
treatment–related grade 2 or higher adverse event (AE)
was observed; subsequently, at least 2 patients were
allocated to each cohort. Sufﬁcient numbers of patients
were enrolled in each cohort to ensure that data for at
least one patient who had completed the ﬁrst 28 days of
dosing were available before deﬁning a new dose and/or
schedule and initiating the subsequent cohort. The doselimiting toxicity (DLT) period was 28 days. After the
second cohort, the dosing recommendation for the next
cohort was made by using the Neuenschwander
Continual Reassessment Method based on the observed
DLT data for all the patients treated under the same
dosing schedule (further details are included in the
Supplementary Materials). The dose increment was no
more than 100% of the current dose in the absence of any
safety signals and no more than 50% of the current dose
if AEs were reported. A safety review was conducted to
evaluate safety parameters, such as those in the primary
end point (i.e., AEs and DLTs), tolerability, and available
PK and PD data, to decide on the next dose or dosing
schedule before recruitment to the next cohort. Any dose
level(s) could have been expanded to include up to 12
patients to collect adequate data on safety, PK, or PD.
In response to patients experiencing DLTs of thrombocytopenia with daily dosing at the higher doses, an
intermittent dosing schedule (3.0 mg for 4 days on and 3
days off) was initiated to investigate whether giving a
predetermined break from dosing would allow recovery
of platelets. Two patients were initially enrolled in the
cohort, but as one patient experienced grade 4 thrombocytopenia, and considering the long half-life (t1/2 ) of
GSK2897552 and the irreversible binding to the target, it
was deemed that a longer break period would be needed
to decrease the risk of grade 3 and higher thrombocytopenia. Thus, the 4 days on and 10 days off dosing
schedules were introduced and no further patients were
enrolled in the 3.0 mg for 4 days on and 3 days off
schedule.

Interventions
GSK2879552 was provided as oral capsules, and the
following dose and schedule combinations were assessed
in nine dose cohorts: daily dosing of 0.25 mg, 0.5 mg, 1.0
mg, 1.5 mg, 2.0 mg, and 3.0 mg and intermittent dosing of
3.0 mg for 4 days on and 3 days off, 3.0 mg for 4 days on
and 10 days off, and 4.0 mg for 4 days on and 10 days off.
The starting dose of 0.25 mg daily was selected on the
basis of ﬁndings from preclinical studies and predicted
minimum anticipated biologically effective dose with the
goal of administering a pharmacologically active dose
that is reasonably safe to use, according to International

Study End Points and Assessments
The primary end point of Part 1 was determination of
the safety, tolerability and recommended phase II
dose(s) and regimen of GSK2879552 by assessing AEs,
DLTs, dose reductions or delays, withdrawals due to
toxicities, and changes in safety parameters. The secondary end points were characterization of PK parameters after single-dose (day 1) and repeat-dose (day 15)
administration of GSK2879552 (including area under the
concentration-time curve [AUC], maximum observed
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concentration [Cmax], time of occurrence of Cmax [Tmax],
terminal phase and/or effective t1/2 , accumulation ratio,
and time invariance), evaluation of clinical response by
measuring the disease control rate (DCR) at week 16,
and evaluation of the relationship between GSK2879552
exposure markers (e.g., dose, Cmax) and safety (e.g.,
platelet levels in blood) and efﬁcacy parameters.
Safety Assessments. Safety assessments included the
monitoring of AEs, clinical laboratory test results, heart
rate, blood pressure, temperature, 12-lead electrocardiogram ﬁndings, Eastern Cooperative Oncology Group
performance status, and physical examination ﬁndings.
PK Assessments. Serial blood samples were collected
for PK analysis on day 1 and day 15 before a dose to 24
hours after a dose. Most patients did not receive a dose
on day 2 to allow for PK sampling at 48 hours after
a dose to better characterize the terminal t1/2 of
GSK2879552. Further predose samples were collected
regularly throughout the study.
The GSK2879552 concentration-time data were
summarized by planned time point and dose cohort. PK
analysis of GSK2879552 by using actual relative time
was conducted by noncompartmental methods using
WinNonlin. Cmax, time of occurrence of Cmax, AUC(0–24)
and/or AUC(0–N) after single-dose administration and
AUC(0–24) after repeated administration, apparent terminal phase elimination rate constant (lz), and t1/2 were
determined. To estimate the extent of accumulation after
repeat dosing, the observed accumulation ratio was
determined from the ratio of AUC(0–24) with a repeated
dose (day 15 or later) to AUC(0–24) on day 1. The ratio of
AUC(0–24) on day 15 to AUC(0–N) on day 1 was calculated
to assess time invariance.
PD Assessments. As KDM1A inhibition results in a
blockage of platelet maturation,15,23 platelet count
changes can be viewed as a PD effect and are expected to
be reﬂective of the level of target engagement. Baseline
platelet counts and nadir values were measured for the
initial dose level and during the ﬁrst 60 days of treatment. The platelet nadir was expressed as percent
change from baseline platelet count.
Efﬁcacy Assessment. Disease assessments, including
imaging and physical examination, were performed
every 8 weeks. Disease progression and response evaluations were determined according to the deﬁnitions in
the Response Evaluation Criteria in Solid Tumors
(RECIST), version 1.1.24 Speciﬁcally, the DCR was
deﬁned as the sum of patients who had a complete
response, partial response, or stable disease at week 16.
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Statistical Methods
No formal hypotheses testing was conducted; all
statistical analyses for safety and efﬁcacy were
descriptive.
PK and PD parameters were summarized using
descriptive statistics by dose cohort. Dose proportionality for Cmax and AUC after single and repeated
administration was evaluated by using power models.
Platelet nadir values expressed as percent change from
baseline were plotted graphically against summary
exposure measures (e.g., dose, Cmax, AUC obtained on
day 1). Only dose cohorts with repeat daily dosing were
included in the analysis (i.e., 0.25-mg–3.0-mg daily dose
cohorts). On the basis of the nature of the relationship, a
sigmoidal maximum effect (Emax) model was ﬁtted to the
data to obtain the slope, with the exposure producing
50% of the Emax (ED50) and Emax. The baseline
effect was set to zero and the upper bound of Emax was
set to –100%.

Results
Study Population
In total, 29 patients were enrolled and allocated to
one of the dose cohorts; 22 patients completed the study
and seven prematurely withdrew, primarily because of
treatment-related AEs (three of 29 [10%]) or withdrawal of consent (two of 29 [7%]) (Supplementary
Fig. 2).
Most patients (18 of 29 [62%]) were in the 18- to 64year-old group, with a mean age of 60.6 (±8.58) years;
most of the patients (18 of 29 [62%]) were male. A
summary of patient demographics is provided in Table 1.

Table 1. Patient Baseline Demographics (N ¼ 29)
Characteristic
Sex
Female
Male
Age group, y
<18
18–64
65–74
>74
Age, y
Mean
SD
Median
Minimum
Maximum
Ethnicity
Hispanic or Latino
Not Hispanic or Latino
Missing

Patients, n (%)
11 (38)
18 (62)
0
18 (62)
10 (34)
1 (3)
60.6
8.58
62.0
44
78
2 (7)
26 (90)
1 (3)
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Safety and Tolerability
Most patients (28 of 29 [97%]) reported at least one
AE, most frequently thrombocytopenia (12 of 29 [41%]),
fatigue (10 of 29 [34%]), and constipation (nine of 29
[31%]). Most patients (24 of 29 [83%]) had at least one
AE that was considered by the investigator to be related
to the study treatment (Table 2). The most frequently
occurring treatment-related AE was thrombocytopenia
(12 of 29 [41%]); eight of these patients had dose reductions or interruptions due to grade 3 or higher
thrombocytopenia. Furthermore, two patients were
withdrawn from the study because of drug-related AEs
(one patient in the 2.0-mg daily group with grade 3
asthenia and one patient in the 3.0-mg daily group with
grade 3 encephalopathy).
During the dose-escalation phase, 12 SAEs were reported in patients who received a dose of 9 mg (Table 3).
Six of the SAEs were deemed by investigators to be
related to the study treatment, the most common of
which was encephalopathy (reported in four patients
[Supplementary Materials and Supplementary Tables 1
and 2]). There was no clear pattern in the timing of
these cases in relation to the dose of study treatment,
and no speciﬁc magnetic resonance imaging changes
were seen (Supplementary Results). The study was put
on hold three times because of cases of encephalopathy.
Three patients died during the study. One death was
due to the treatment-related SAE of grade 5 encephalopathy in the 2.0-mg daily cohort. The patient in the 3.0mg daily dosing cohort who had a treatment-related SAE
of grade 3 encephalopathy subsequently died 40 days
after the event because of disease progression. One
death was due to an SAE of tumor lysis syndrome in the
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4.0-mg for 4 days on and 10 days off cohort. The event
occurred 14 days after the start of study treatment, and
the patient died 4 days later; it was deemed by the
investigator as unrelated to study treatment.
There were no DLTs in the 0.25-mg, 0.5-mg, 1.0-mg,
or 1.5-mg GSK2879552 daily cohorts and one DLT in the
2.0-mg daily group (the fatal SAE was encephalopathy).
Protocol amendments were made to exclude patients
considered at risk of encephalopathy (those with prior
therapy with temozolomide and/or poly(adenosine
diphosphate–ribose) polymerase [PARP] inhibitors) and
to withhold study treatment if the baseline Montreal
Cognitive Assessment score fell to less than 22 or
decreased by three or more points from baseline. Additional patients were subsequently recruited to the 2.0mg and 3.0-mg daily cohorts according to the planned
study design, and in parallel, intermittent dosing was
initiated. Three patients in the 3.0-mg daily dosing group
had DLTs (grade 4 thrombocytopenia). One patient in
the 3.0-mg for 4 days on and 10 days off dose group had
a DLT (grade 3 encephalopathy) that did not resolve
after withdrawal of the investigational product; the
relationship of the event to the study treatment was not
established, as the patient also had carcinomatous
meningitis, which potentially contributed to the
encephalopathy.
Eight patients (28%) had at least one dose reduction;
all were due to grade 3 or 4 thrombocytopenia, and
seven of the eight patients were receiving doses of at
least 2.0 mg of GSK2879552. A total of 18 patients (62%)
had dose interruptions of GSK2879552; 44% of the dose
interruptions were due to AEs. No patient had a grade 3
or higher increase from baseline in clinical laboratory

Table 2. Summary of Treatment-Related AEs by Frequency (7%) (N ¼ 29)
Maximum Grade, n (%)
AE

Patients, n (%)

1

Any AE
Thrombocytopenia
Fatigue
Decreased appetite
Anemia
Nausea
Neutropenia
Encephalopathy
Asthenia
Abdominal pain
Chills
Constipation
Diarrhea
Dysgeusia
Platelet count decreased
White blood cell count decreased

24 (83)
12 (41)
8 (28)
7 (24)
6 (21)
5 (17)
5 (17)
4 (14)
3 (10)
2 (7)
2 (7)
2 (7)
2 (7)
2 (7)
2 (7)
2 (7)

5
2
4
3
4
4
1
0
0
2
2
0
2
2
2
2

AE, adverse event.

2
(17)
(7)
(14)
(10)
(14)
(14)
(3)
(0)
(0)
(7)
(7)
(0)
(7)
(7)
(7)
(7)

6
0
4
4
1
1
2
1
1
0
0
2
0
0
0
0

3
(21)
(0)
(14)
(14)
(3)
(3)
(7)
(3)
(3)
(0)
(0)
(7)
(0)
(0)
(0)
(0)

5
4
0
0
1
0
1
2
2
0
0
0
0
0
0
0

4
(17)
(14)
(0)
(0)
(3)
(0)
(3)
(7)
(7)
(0)
(0)
(0)
(0)
(0)
(0)
(0)

7
6
0
0
0
0
1
0
0
0
0
0
0
0
0
0

5
(24)
(21)
(0)
(0)
(0)
(0)
(3)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)

1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0

(3)
(0)
(0)
(0)
(0)
(0)
(0)
(3)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
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evaluations deemed to be related to the study treatment
(other than thrombocytopenia).

9 (31%)
12
6
2
1

Total
(N ¼ 29)

October 2019

2 (100%)
3
0
1
0

The PK concentration-time data showed a rapid increase in GSK2879552 concentration, with the maximum
concentration achieved within 2 hours (Fig. 1).
Single- and repeat-dose PK parameters are summarized in Table 4. GSK2879552 was eliminated slowly,
with an average terminal phase effective t1/2 of 18 hours
at the 2-mg daily dose. Cmax and AUC values generally
increased in a dose-proportional manner over the 0.25mg to 3.0-mg daily dose range at both day 1 and day
15 (Supplementary Table 3).
Accumulation ratio based on AUC was assessed for
the GSK2879552 1.0-mg, 2.0-mg, and 3.0-mg daily
groups, as these cohorts each had at least three patients.
The results showed a moderate accumulation of
GSK2879552 with daily administration from day 1 to
day 15, which is in line with the terminal phase effective
t1/2 (Supplementary Table 4).

0
0
0
0
0
1 (33%)
2
2
0
0

2 (40%)
2
1
0
0

3.0 mg 4 d
on/3 d off
(n ¼ 2)
3.0 mg
daily
(n ¼ 3)

3.0 mg 4 d
on/10 d off
(n ¼ 5)

4.0 mg 4 d
on/10 d off
(n ¼ 2)

PK Analyses

All dose cohorts had a negative mean percent
change from baseline platelet count to nadir value
(Supplementary Table 5). The percent decrease in
platelet count generally increased across the daily dosing
range; patients in the GSK2879552 3.0-mg daily group
had the greatest drop (–94.7%). Doubling the dose of
GSK2879552 from 1.0 mg to 2.0 mg daily led to a dramatic decrease in platelet count (mean percent change
from the baseline platelet count to a nadir value of
–25.4% to –78.2%). Individual platelet counts over time
in the 2.0-mg and 3.0-mg daily groups are shown in

2 (67%)
2
1
0
0
0
0
0
0
0

2 (29%)
3
2
1
1

1.5 mg
daily
(n ¼ 3)
1.0 mg
daily
(n ¼ 5)

2.0 mg
daily
(n ¼ 7)

PD Analyses

SAE, serious adverse event.

Mean (SD) GSK2879552 plasma concentration (ng/mL)

0
0
0
0
0
0
0
0
0
0
Patients with SAEs, n
SAEs, n
Drug-related SAEs, n
Fatal SAEs, n
Drug-related fatal SAEs, n

Parameter

Table 3. Summary of SAEs

0.25 mg
daily
(n ¼ 1)

0.5 mg
daily
(n ¼ 1)

40

0.25 mg daily (n = 1)
0.5 mg daily (n = 1)
1.0 mg daily (n = 5)
1.5 mg daily (n = 3)
2.0 mg daily (n = 7)
3.0 mg daily (n = 3)

35
30
25
20
15
10
5
0
0

4

8

12

16

20
24
28
Time (hours)

32

36

40

44

48

Figure 1. Mean (SD) GSK2879552 plasma concentration
versus time after a single dose.

Parameter

0.5 mg
daily
(n ¼ 1)

1.0 mg
daily
(n ¼ 5)

1.5 mg
daily
(n ¼ 3)

2.0 mg
daily
(n ¼ 7)

3.0 mg
daily
(n ¼ 3)

3.0 mg 4 d
on/3 d off
(n ¼ 2)

3.0 mg 4 d
on/10 d off
(n ¼ 5)

4.0 mg 4 d
on/10 d off
(n ¼ 2)

1
3.8
—

1
2.9
—

5
6.4
17.3

3
9.3
12.2

7
12.9
36.6

3
22.0
42.9

2
31.2
26.8

5
23.9
20.8

2
23.4
68.8

1
0.5
—

1
1.5
—

5
0.5
0.5, 0.5

3
1.5
0.5, 2.9

7
0.5
0.3, 3.0

3
2.0
1.0, 2.1

2
1.0
0.5, 1.4

5
1.5
0.6, 2.0

2
0.8
0.5, 1.0

1
10.4
—

1
16.2
—

5
27.8
12.7

3
60.8
14.1

6
77.0
52.2

3
159.0
30.5

2
138.0
19.1

5
155.8
29.1

1
154.9
—

1
14.5
—

1
27.2
—

5
40.0
18.7

3
70.7
15.0

6
108.6
56.1

3
206.3
27.7

2
163.6
25.3

5
182.9
27.1

1
180.9
—

1
16.9
—

1
24.0
—

5
17.3
62.6

3
8.8
8.7

6
18.1
8.7

3
15.4
19.1

2
11.5
47.9

5
8.9
23.2

1
8.4
—

1
3.4
—

1
4.3
—

5
6.9
29.2

1
13.8
—

5
15.7
39.4

3
15.2
23.1

2
24.4
21.5

5
28.1
7.7

0

1
1.0
—

1
1.5
—

5
1.0
0.5, 2.1

1
0.5
—

5
1.0
0.5, 4.0

3
1.5
0.7, 3.0

2
1.5
1.0, 2.0

5
1.1
0.5, 1.5

0

1
27.3
—

1
40.3
—

5
53.3
31.2

1
91.1
—

5
143.8
64.2

3
141.9
32.4

2
164.7
8.2

4
203.4
37.2

0
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Cmax, maximum concentration; %CVb, percent coefﬁcient of variation; Min, minimum; Max, maximum; AUC(0–24), area under the concentration-time curve from time zero (before dose) to 24 hours after dose;
AUC(0–N), area under the concentration-time curve from time zero (before dose) extrapolated to inﬁnite time; T1/2z, half-life lambda z; Tmax, time of Cmax.
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Day 1
Cmax, ng/mL
n
Geometric mean
%CVb
Tmax, h
n
Median
Min, max
AUC(0–24), h*ng/mL
n
Geometric mean
%CVb
AUC(0–N), h*ng/mL
n
Geometric mean
%CVb
T1/2z, h
n
Geometric mean
%CVb
Day 15 (or later)
Cmax, ng/mL
n
Geometric mean
%CVb
Tmax, h
n
Median
Min, max
AUC(0–24), h*ng/mL
n
Geometric mean
%CVb

0.25 mg
daily
(n ¼ 1)
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Table 4. Summary of Derived Plasma Pharmacokinetic Parameters on Day 1 and Day 15
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Figure 2. In the 3.0-mg group, platelets started to
decrease shortly after initiation of treatment, with a
similar rate of decrease observed in all three patients

A

400

1835

and the nadir observed around day 14. A similar recovery time after dose interruptions and/or reduction
was also observed in all three patients.

* Dose interruption
+ Dose reduction

Platelet count (g/L)

300

200

100

0

G1
G2
G3
G4
-10

0

10

20
30
Study day

40

50

60

B
250

Dose interruption
+ Dose reduction

Platelet count (g/L)

200

150

100

G1
G2

50
G3
G4
0
-10

0

10

20
30
Study day

40
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Figure 2. Time course of platelet count in individual patients who received 2 mg (A) or 3 mg (B) of GSK2879552 daily. Marks
for dose interruptions (asterisk) and reductions (plus sign) show the dose administered on the day of the platelet counts but
may not coincide with the exact day on which the dose interruption/reduction was started. The absence of a mark after a
dose interruption means that treatment was restarted at the same dose. Grade (G) of toxicity is denoted as G1 to G4. No
change in dose was required for G1. With G2 thrombocytopenia, the dose was either continued with no change or held for up
to 2 weeks for toxicity to resolve to baseline or grade 1 or lower and then continued at the same dose, or reduced by no more
than 25% if considered a dose-limiting toxicity. In the case of G3 and G4 events, the dose was held for up to 2 weeks for
toxicity to resolve to baseline or grade 1 or lower and then reduced by no more than 25%; if recovery was achieved after 14
days, the patient was withdrawn.
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The model parameters for a sigmoidal Emax model
describing the relationship between platelet nadir and
dose, day 1 Cmax, or AUC(0–N) are shown in
Supplementary Figure 3 and Supplementary Table 6. The
relationships are very steep, as is shown by the hill
coefﬁcients ranging from 2.2 to 3.5. The dose estimated
to provide 50% of the Emax on platelets was between 1.3
and 1.7 mg, indicating signiﬁcant target engagement in
the dose range tested.

Efﬁcacy Results
The DCR was 14% (four of 29 patients) at 16 weeks
(Supplementary Table 7). A best response of stable disease was reported for two of 29 patients (7%); two
patients did not meet the criteria of best overall
response of stable disease. A patient narrative for one
of the patients with stable disease is provided in
Supplementary Materials.

Discussion
This study aimed to evaluate the safety, tolerability,
PK, PD, and clinical activity of the KDM1A inhibitor
GSK2879552 for the treatment of patients with relapsed
or refractory SCLC. Speciﬁcally, Part 1 was designed to
assess the safety of GSK2879552 and determine the
recommended dose and Part 2 was planned to further
evaluate the safety and tolerability of GSK2879552 at the
recommended dose and determine clinical activity.
However, AEs were common with GSK2879552 and
included six drug-related SAEs, one of which was fatal.
Although there were no complete or partial responses
across all dose levels, the impact of the two observed
responses of stable disease should not be underestimated, given the patient histories. The remaining
patients either progressed or withdrew as a result of
AEs. The investigators concluded that the risk-beneﬁt
proﬁle of GSK2879552 in relapsed or refractory SCLC
did not favor continuation of the study.
The GSK2879552 PK were characterized by very
rapid absorption, with maximum concentrations achieved within 2 hours of dosing and by slow elimination,
with a terminal t1/2 of 18 hours with the 2.0-mg daily
dose. Exposure tended to increase in a dose-proportional
manner after single and repeated administration and to
be higher with repeated administration in line with the
long t1/2 .
Overall, 28 of the 29 patients (97%) reported at least
one AE during the study, the most common of which
were thrombocytopenia or fatigue. Thrombocytopenia
was an on-target effect and was anticipated on the basis
of preclinical ﬁndings in rats and dogs, in which a steep
dose-exposure platelet decrease was observed (data on
ﬁle). At their starting dose level, no patients experienced
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thrombocytopenia with 0.25 mg or 0.5 mg, and grade 1
thrombocytopenia was observed with 1.0 mg and 1.5 mg
daily; however, grade 3 thrombocytopenia was observed
in most patients receiving 2.0 mg who completed the
study, and grade 4 was observed in all three patients
receiving 3.0 mg daily. It should be noted that the patient
who started treatment at 0.25 mg was dose-escalated to
0.5 mg (grade 1 thrombocytopenia) and then to 1.0 mg,
the dose at which grade 4 thrombocytopenia was
observed. Correspondingly, a steep sigmoidal Emax relationship was observed between the extent of thrombocytopenia and dose, Cmax, or AUC of GSK2879552.
Although a median –13.5% decrease in platelet count
was observed with a 1.0-mg daily dose (n ¼ 5), the
median was –87.1% with a 2.0-mg dose (n ¼ 5), showing
that a doubling in dose translated to a dramatic increase
in the thrombocytopenic effect of GSK2879552. The
median maximum change from baseline was 95% with
the 3.0-mg daily dose. These observations led to evaluation of the intermittent dosing schedule to allow for
similar doses or higher doses to be administered and
tolerated. The 3.0-mg for 4 days on and 3 days off
schedule provided a limited reduction of the effect on
the platelet count (26% and 86% reductions), which is in
line with the long t1/2 of GSK2879552. The 3.0-mg 4
days on and 10 days off intermittent dosing schedule,
with a longer break between dosing cycles, allowed for a
reduced impact on the platelets, with a lower median
reduction of 59% (range 52%–75%). The 4 days on and
10 days off cohort did not provide exposure high enough
to conﬁrm any beneﬁt of this schedule. Tumor-speciﬁc
gene expression changes were also used to monitor
target engagement in preclinical models.15 Although
dose-limiting thrombocytopenia did not allow for prolonged daily administration beyond 1.5 mg/kg of
GSK2879552, doses up to 135 mg/kg were tolerated for
up to 5 days of daily administration. Moreover, doseresponse studies in mice indicated that changes in tumor gene expression continued to increase in magnitude
well beyond the maximally tolerated dose. The dose at
which the platelet maximal tolerated dose was reached
resulted in approximately 50% of the maximal gene
expression change; therefore, although the current study
revealed target engagement and grade 3 or 4 thrombocytopenia, this likely reﬂects only 50% of maximal PD,
suggesting that complete biological response may have
been dose-limited.15 Together, these results are consistent with the important role that KDM1A plays in hematopoiesis and with previous ﬁndings that KDM1A
knockdown in mice inhibits platelet production.23
Four patients experienced events of encephalopathy,
one of which was fatal and eventually led to termination
of the study. The ﬁrst two patients had been previously
exposed to temozolomide with or without a PARP
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inhibitor (as part of a randomized controlled clinical
trial) and had received prophylactic cranial irradiation
(PCI). These were initially considered to be predisposing
factors; however, the third patient to experience encephalopathy had not received PCI, and the fourth
had not been exposed to temozolomide or PARP inhibitors. Overall, 75% of patients in this study had
received PCI previously, and most did not experience
encephalopathy. Furthermore, the exposure and platelet
decreases in patients who experienced encephalopathy
were within the range of values observed in the other
patients.
Although encephalopathy was not anticipated on the
basis of preclinical studies, KDM1A is known to be
important in brain development and function. Loss of
KDM1A in adult mice induced transcriptional changes in
neurodegeneration pathways, with increased stem cell
gene expression in the hippocampus, and resulted in
paralysis, hippocampus and cortex neurodegeneration,
and memory impairment.25 KDM1A has also been
shown to be important for neuronal differentiation
and the regulation of neuron-speciﬁc gene expression
programs.26
Furthermore, a preclinical study in a rat model
revealed that [14C]GSK2879552-related material was
distributed into central nervous system tissues (data on
ﬁle), suggesting that GSK2879552 is able to cross the
blood-brain barrier. Thus, GSK2879552 may lead to
gene deregulation in the brain, potentially leading to
encephalopathy.
Several other KDM1A inhibitors are in development
for potential cancer therapies. Treatment of AML cell
lines and a xenograft model with the cyclopropylaminebased irreversible KDM1A inhibitor RN-1 led to
inhibition of tumor cell growth and increased cellular
differentiation.27 Another study found the combination
treatment of an irreversible KDM1A inhibitor T-3775440
with the neural precursor cell expressed, developmentally down-regulated 8–activating enzyme inhibitor
pevonedistat resulted in synergistic growth inhibition of
AML cells and improved survival in a tumor xenograft
model of AML.28 The KDM1A inhibitor ORY-1001 was
investigated in a multicenter phase I study in relapsed or
refractory acute leukemia.29 Select biomarkers indicated
a dose-dependent response with ORY-1001; however,
AEs were common, and consistent with our study,
thrombocytopenia occurred in some patients (seven
events in ﬁve of 27 patients). In an extension cohort
(n ¼ 14), objective responses were observed in ﬁve
patients and ORY-1001 promoted blast cell differentiation in nine patients. Encephalopathy was not observed
in these studies of leukemia. Together, these ﬁndings
highlight the therapeutic potential of KDM1A inhibitors
in cancer, but there is also a risk of side effects, such as
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encephalopathy, although thrombocytopenic effects may
prevent the desired exposure from being achieved.
In conclusion, KDM1A is an epigenetic regulator that
is highly expressed in primary SCLC. GSK2879552 is a
potent, selective inhibitor of KDM1A and has favorable
PK properties in patients with SCLC. Although the
thrombocytopenic effects of GSK2879552 indicate that it
successfully inhibited KDM1A in patients, it resulted in
poor DCRs and high rates of AEs, including four events of
encephalopathy, leading to the termination of the study.

Data Sharing Statement
Within 6 months of this publication, anonymized individual participant data, the annotated case report form,
protocol, reporting and analysis plan, data set speciﬁcations, raw data set, analysis-ready data set, and clinical
study report will be available for research proposals
approved by an independent review committee. Proposals
should be submitted to www.clinicalstudydatarequest.
com. A data access agreement will be required.
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